Hereditary ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 69, Issue 1, 2009, Pages 28-44

  Russo, Antonio ^a   Calò, Valentina ^a   Bruno, Loredana ^a   Rizzo, Sergio ^a   Bazan, Viviana ^a   Di Fede, Gaetana ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

BRCA; Genetic testing; Hereditary ovarian cancer; HNPCC; Prophylactic surgery

Indexed keywords

CA 125 ANTIGEN;

BREAST CANCER; CANCER SCREENING; CANCER SURGERY; CANCER SUSCEPTIBILITY; COLOR ULTRASOUND FLOWMETRY; COLORECTAL CANCER; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; ONCOGENE; OVARY CANCER; REVIEW; RISK REDUCTION; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; TREATMENT INDICATION;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 56449084421     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.06.003     Document Type: Review

References (164)

1. Hanna L., and Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 20 (2006) 339-362
2. Hankinson S.E., Colditz G.A., Hunter D.J., et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76 (1995) 284-290
3. Narod S.A., Goldgar D., Cannon-Albright L., et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 64 (1995) 394-398
4. Godard B., Foulkes W.D., Provencher D., et al. Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol 179 (1998) 403-410
5. Stratton J.F., Pharoah P., Smith S.K., et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 105 (1998) 493-499
6. Werness B.A., and Eltabbakh G.H. Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features. Int J Gynecol Pathol 20 (2001) 48-63
7. Auranen A., Pukkala E., Makinen J., et al. Cancer incidence in the first-degree relatives of ovarian cancer patients. Br J Cancer 74 (1996) 280-284
8. Claus E.B., Schildkraut J.M., Thompson W.D., and Risch N.J. The genetic attributable risk of breast and ovarian cancer. Cancer 77 (1996) 2318-2324
9. Couch F.J., and Weber B.L. Breast Cancer. In: Vogelstein B., and Kinzler K.W. (Eds). The genetic basis of human cancer (1998), McGraw-Hill, New York 537-563
10. Srivastava A., McKinnon W., and Wood M.E. Risk of breast and ovarian cancer in women with strong family histories. Oncology (Williston Park) 15 (2001) 889-902 discussion 902, 905-887, 911-813
11. Kasprzak L., Foulkes W.D., and Shelling A.N. Forth nightly review: hereditary ovarian carcinoma. BMJ 318 (1999) 786-789
12. Balmain A., Gray J., and Ponder B. The genetics and genomics of cancer. Nat Genet 33 Suppl. (2003) 238-244
13. Kinzler K.W., and Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386 (1997) 761-763
14. Lynch H.T., Fitzsimmons M.L., Conway T.A., et al. Hereditary carcinoma of the ovary and associated cancers: a study of two families. Gynecol Oncol 36 (1990) 48-55
15. Prat J., Ribe A., and Gallardo A. Hereditary ovarian cancer. Hum Pathol 36 (2005) 861-870
16. Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 88 (2003) S8-S10 discussion S11-13
17. Lynch H.T., Shaw M.W., Magnuson C.W., et al. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 117 (1966) 206-212
18. Lynch H.T., Shaw T.G., and Lynch J.F. Inherited predisposition to cancer: a historical overview. Am J Med Genet C Semin Med Genet 129 (2004) 5-22
19. Risch H.A., McLaughlin J.R., Cole D.E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68 (2001) 700-710
20. Boardman L.A., Thibodeau S.N., Schaid D.J., et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 128 (1998) 896-899
21. Gorlin R.J. Nevoid basal cell carcinoma syndrome. Dermatol Clin 13 (1995) 113-125
22. Nelen M.R., Padberg G.W., Peeters E.A., et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 13 (1996) 114-116
23. Pharoah P.D., and Ponder B.A. The genetics of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16 (2002) 449-468
24. Easton D.F., Bishop D.T., Ford D., and Crockford G.P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52 (1993) 678-701
25. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (1998) 676-689
26. Gayther S.A., Warren W., Mazoyer S., et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11 (1995) 428-433
27. Russo A., Calo V., Agnese V., et al. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses. Breast Cancer Res Treat 105 (2007) 267-276
28. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
29. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378 (1995) 789-792
30. Tavtigian S.V., Simard J., Rommens J., et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12 (1996) 333-337
31. Carter R.F. BRCA1, BRCA2 and breast cancer: a concise clinical review. Clin Invest Med 24 (2001) 147-157
32. Deng C.X., and Brodie S.G. Roles of BRCA1 and its interacting proteins. Bioessays 22 (2000) 728-737
33. Scully R. Role of BRCA gene dysfunction in breast and ovarian cancer predisposition. Breast Cancer Res 2 (2000) 324-330
34. Narod S.A., and Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4 (2004) 665-676
35. Buffone A., Capalbo C., Ricevuto E., et al. Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. Breast Cancer Res Treat 106 (2007) 289-296
36. Falchetti M., Lupi R., Rizzolo P., et al. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat (2007)
37. Veschi S., Aceto G., Scioletti A.P., et al. High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability. Ann Oncol 18 Suppl. 6 (2007) vi86-vi92
38. Mazoyer S. Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 25 (2005) 415-422
39. Antoniou A.C., Pharoah P.D., McMullan G., et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 86 (2002) 76-83
40. Ramus S.J., Harrington P.A., Pye C., et al. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat 28 (2007) 1207-1215
41. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 (2003) 1117-1130
42. Weiss J.R., Moysich K.B., and Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 20-26
43. Hall J.M., Lee M.K., Newman B., et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 (1990) 1684-1689
44. Gayther S.A., Mangion J., Russell P., et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15 (1997) 103-105
45. Sowter H.M., and Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 26 (2005) 1651-1656
46. Thompson D., and Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68 (2001) 410-419
47. Offit K., Levran O., Mullaney B., et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95 (2003) 1548-1551
48. Ferla R., Calo V., Cascio S., et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18 Suppl. 6 (2007) vi93-vi98
49. Antoniou A.C., Pharoah P.D., Narod S., et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42 (2005) 602-603
50. Brose M.S., Rebbeck T.R., Calzone K.A., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94 (2002) 1365-1372
51. Friedman L.S., Szabo C.I., Ostermeyer E.A., et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 57 (1995) 1284-1297
52. Giordano S.H. A review of the diagnosis and management of male breast cancer. Oncologist 10 (2005) 471-479
53. Liede A., Karlan B.Y., and Narod S.A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22 (2004) 735-742
54. Roa B.B., Boyd A.A., Volcik K., and Richards C.S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14 (1996) 185-187
55. Robles-Diaz L., Goldfrank D.J., Kauff N.D., et al. Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 3 (2004) 259-264
56. Rubinstein W.S. Hereditary breast cancer in Jews. Fam Cancer 3 (2004) 249-257
57. Satagopan J.M., Boyd J., Kauff N.D., et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8 (2002) 3776-3781
58. Struewing J.P., Abeliovich D., Peretz T., et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11 (1995) 198-200
59. Dorum A., Hovig E., Trope C., et al. Three percent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. Eur J Cancer 35 (1999) 779-781
60. Thorlacius S., Olafsdottir G., Tryggvadottir L., et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13 (1996) 117-119
61. Thorlacius S., Sigurdsson S., Bjarnadottir H., et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60 (1997) 1079-1084
62. Pandit S.N., and Desai S.P. Genetics of ovarian cancer. Rev Gynaecol Pract 4 (2004) 27-31
63. Aarnio M., Sankila R., Pukkala E., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81 (1999) 214-218
64. Lancaster J.M., Powell C.B., Kauff N.D., et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107 (2007) 159-162
65. Cook J. Family history of ovarian cancer. Curr Obstet Gynaecol 12 (2002) 47-51
66. Watson P., Butzow R., Lynch H.T., et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 82 (2001) 223-228
67. Drake A.C., Campbell H., Porteous M.E., and Dunlop M.G. The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer. Int J Gynecol Cancer 13 (2003) 262-277
68. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21 (2003) 1174-1179
69. Wheeler J.M., Bodmer W.F., and Mortensen N.J. DNA mismatch repair genes and colorectal cancer. Gut 47 (2000) 148-153
70. Arzimanoglou I.I., Lallas T., Osborne M., et al. Microsatellite instability differences between familial and sporadic ovarian cancers. Carcinogenesis 17 (1996) 1799-1804
71. Buermeyer A.B., Deschenes S.M., Baker S.M., and Liskay R.M. Mammalian DNA mismatch repair. Annu Rev Genet 33 (1999) 533-564
72. Christmann M., Tomicic M.T., Roos W.P., and Kaina B. Mechanisms of human DNA repair: an update. Toxicology 193 (2003) 3-34
73. Thibodeau S.N., Bren G., and Schaid D. Microsatellite instability in cancer of the proximal colon. Science 260 (1993) 816-819
74. Brown G.J., St John D.J., Macrae F.A., and Aittomaki K. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol 80 (2001) 346-349
75. Zaykin D.V., Westfall P.H., Young S.S., et al. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 53 (2002) 79-91
76. Song H., Ramus S.J., Quaye L., et al. Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis 27 (2006) 2235-2242
77. Pieretti M., Cavalieri C., Conway P.S., et al. Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 64 (1995) 434-440
78. Vasen H.F., Mecklin J.P., Khan P.M., and Lynch H.T. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34 (1991) 424-425
79. Hendriks Y.M., de Jong A.E., Morreau H., et al. Diagnostic approach and management of lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 56 (2006) 213-225
80. Rodriguez-Bigas M.A., Boland C.R., Hamilton S.R., et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89 (1997) 1758-1762
81. Hendriks Y., Franken P., Dierssen J.W., et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 162 (2003) 469-477
82. Lothe R.A., Peltomaki P., Meling G.I., et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53 (1993) 5849-5852
83. Moslein G., Tester D.J., Lindor N.M., et al. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 5 (1996) 1245-1252
84. Lindor N.M., Burgart L.J., Leontovich O., et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20 (2002) 1043-1048
85. Bourne T.H., Campbell S., Reynolds K., et al. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol 52 (1994) 379-385
86. Hoskins K.F., Stopfer J.E., Calzone K.A., et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA 273 (1995) 577-585
87. Olopade O.I., and Pichert G. Cancer genetics in oncology practice. Ann Oncol 12 (2001) 895-908
88. Cella D., Hughes C., Peterman A., et al. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol 21 (2002) 564-572
89. Van Riper M., and McKinnon W.C. Genetic testing for breast and ovarian cancer susceptibility: a family experience. J Midwifery Womens Health 49 (2004) 210-219
90. Couch F.J., DeShano M.L., Blackwood M.A., et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336 (1997) 1409-1415
91. Domchek S.M., Eisen A., Calzone K., et al. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 21 (2003) 593-601
92. Frank T.S., Manley S.A., Olopade O.I., et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16 (1998) 2417-2425
93. Parmigiani G., Berry D., and Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62 (1998) 145-158
94. Shattuck-Eidens D., Oliphant A., McClure M., et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278 (1997) 1242-1250
95. Contegiacomo A., Pensabene M., Capuano I., et al. An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer. Ann Oncol 15 (2004) 726-732
96. Eccles D.M. Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics. Ann Oncol 15 Suppl. 4 (2004) iv133-iv138
97. Thull D.L., and Vogel V.G. Recognition and management of hereditary breast cancer syndromes. Oncologist 9 (2004) 13-24
98. Judkins T., Hendrickson B.C., Deffenbaugh A.M., and Scholl T. Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1. Mutat Res 573 (2005) 168-179
99. Berchuck A., Heron K.A., Carney M.E., et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 4 (1998) 2433-2437
100. Piver M.S. Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry. Gynecol Oncol 85 (2002) 9-17
101. Lakhani S.R., Manek S., Penault-Llorca F., et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 10 (2004) 2473-2481
102. Lux M.P., Fasching P.A., and Beckmann M.W. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84 (2006) 16-28
103. Rubin S.C., Benjamin I., Behbakht K., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335 (1996) 1413-1416
104. Ben David Y., Chetrit A., Hirsh-Yechezkel G., et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20 (2002) 463-466
105. Aida H., Takakuwa K., Nagata H., et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4 (1998) 235-240
106. Buller R.E., Shahin M.S., Geisler J.P., et al. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 8 (2002) 1196-1202
107. Johannsson O.T., Ranstam J., Borg A., and Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16 (1998) 397-404
108. Chabalier C., Lamare C., Racca C., et al. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5 (2006) 1001-1007
109. Boks D.E., Trujillo A.P., Voogd A.C., et al. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 102 (2002) 198-200
110. MacDonald N.D., and Jacobs I.J. Is there a place for screening in ovarian cancer?. Eur J Obstet Gynecol Reprod Biol 82 (1999) 155-157
111. Olivier R.I., Lubsen-Brandsma M.A., Verhoef S., and van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 100 (2006) 20-26
112. Smith L.H., and Oi R.H. Detection of malignant ovarian neoplasms: a review of the literature. I. Detection of the patient at risk; clinical, radiological and cytological detection. Obstet Gynecol Surv 39 (1984) 313-328
113. Dorum A., Kristensen G.B., Abeler V.M., et al. Early detection of familial ovarian cancer. Eur J Cancer 32A (1996) 1645-1651
114. Karlan B.Y., and Platt L.D. Ovarian cancer screening. The role of ultrasound in early detection. Cancer 76 (1995) 2011-2015
115. Van Nagell Jr. J.R., DePriest P.D., Puls L.E., et al. Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography. Cancer 68 (1991) 458-462
116. Fleischer A.C., Cullinan J.A., Peery C.V., and Jones III H.W. Early detection of ovarian carcinoma with transvaginal color Doppler ultrasonography. Am J Obstet Gynecol 174 (1996) 101-106
117. Weiner Z., Beck D., Shteiner M., et al. Screening for ovarian cancer in women with breast cancer with transvaginal sonography and color flow imaging. J Ultrasound Med 12 (1993) 387-393
118. Bourne T.H., Campbell S., Reynolds K.M., et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 306 (1993) 1025-1029
119. Bourne T.H., Whitehead M.I., Campbell S., et al. Ultrasound screening for familial ovarian cancer. Gynecol Oncol 43 (1991) 92-97
120. Jacobs I.J., Skates S.J., MacDonald N., et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353 (1999) 1207-1210
121. Hogg R., and Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 22 (2004) 1315-1327
122. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-5.
123. Hankinson S.E., Colditz G.A., Hunter D.J., et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 80 (1992) 708-714
124. Piver M.S., Baker T.R., Jishi M.F., et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 71 (1993) 582-588
125. Narod S.A., Risch H., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339 (1998) 424-428
126. Modan B., Hartge P., Hirsh-Yechezkel G., et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345 (2001) 235-240
127. Ursin G., Henderson B.E., Haile R.W., et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?. Cancer Res 57 (1997) 3678-3681
128. Narod S.A., Dube M.P., Klijn J., et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94 (2002) 1773-1779
129. Kennedy R.D., Quinn J.E., Johnston P.G., and Harkin D.P. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360 (2002) 1007-1014
130. McLaughlin J.R., Risch H.A., Lubinski J., et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8 (2007) 26-34
131. Piver M.S., Jishi M.F., Tsukada Y., and Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71 (1993) 2751-2755
132. Struewing J.P., Watson P., Easton D.F., et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr (1995) 33-35
133. Tobacman J.K., Greene M.H., Tucker M.A., et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 2 (1982) 795-797
134. Colgan T.J., Murphy J., Cole D.E., et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25 (2001) 1283-1289
135. Lu K.H., Garber J.E., Cramer D.W., et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18 (2000) 2728-2732
136. Coukos G., and Rubin S.C. Prophylactic oophorectomy. Best Pract Res Clin Obstet Gynaecol 16 (2002) 597-609
137. Colditz G.A., Willett W.C., Stampfer M.J., et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 316 (1987) 1105-1110
138. Aitken J.M., Hart D.M., Anderson J.B., et al. Osteoporosis after oophorectomy for non-malignant disease in premenopausal women. Br Med J 2 (1973) 325-328
139. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
140. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273 (1995) 491-497
141. Burke W., Daly M., Garber J., et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277 (1997) 997-1003
142. Grann V.R., Panageas K.S., Whang W., et al. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 16 (1998) 979-985
143. Schrag D., Kuntz K.M., Garber J.E., and Weeks J.C. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336 (1997) 1465-1471
144. van Roosmalen M.S., Verhoef L.C., Stalmeier P.F., et al. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J Clin Oncol 20 (2002) 2092-2100
145. Rebbeck T.R., Levin A.M., Eisen A., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 (1999) 1475-1479
146. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (2002) 1609-1615
147. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (2002) 1616-1622
148. Scheuer L., Kauff N., Robson M., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 (2002) 1260-1268
149. Finch A., Beiner M., Lubinski J., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296 (2006) 185-192
150. Eisen A., Lubinski J., Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23 (2005) 7491-7496
151. Meijers-Heijboer E.J., Verhoog L.C., Brekelmans C.T., et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355 (2000) 2015-2020
152. Wagner T.M., Moslinger R., Langbauer G., et al. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer 82 (2000) 1249-1253
153. Fry A., Rush R., Busby-Earle C., and Cull A. Deciding about prophylactic oophorectomy: what is important to women at increased risk of ovarian cancer?. Prev Med 33 (2001) 578-585
154. Meiser B., Tiller K., Gleeson M.A., et al. Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer. Psychooncology 9 (2000) 496-503
155. Swisher E. Hereditary cancers in obstetrics and gynecology. Clin Obstet Gynecol 44 (2001) 450-463
156. Rebbeck T.R., Friebel T., Wagner T., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23 (2005) 7804-7810
157. Reich H. Issues surrounding surgical menopause. Indications and procedures. J Reprod Med 46 (2001) 297-306
158. Paley P.J., Swisher E.M., Garcia R.L., et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 80 (2001) 176-180
159. Hankinson S.E., Hunter D.J., Colditz G.A., et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270 (1993) 2813-2818
160. Narod S.A., Sun P., Ghadirian P., et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 357 (2001) 1467-1470
161. Schwartz P.E. The role of prophylactic oophorectomy in the avoidance of ovarian cancer. Int J Gynaecol Obstet 39 (1992) 175-184
162. Gross C.P., Nicholson W., and Powe N.R. Factors affecting prophylactic oophorectomy in postmenopausal women. Obstet Gynecol 94 (1999) 962-968
163. Piver M.S. Prophylactic oophorectomy: reducing the U.S. death rate from epithelial ovarian cancer. A continuing debate. Oncologist 1 (1996) 326-330
164. Smith R.A., Cokkinides V., von Eschenbach A.C., et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 52 (2002) 8-22